LVRNA021
/ AIM Vaccine
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
November 27, 2023
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
(clinicaltrials.gov)
- P2 | N=450 | Active, not recruiting | Sponsor: AIM Vaccine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Sep 2023 ➔ Dec 2024
Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL2
November 22, 2023
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: AIM Vaccine Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL13 • IL2 • IL4
September 07, 2023
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: AIM Vaccine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 12, 2023
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
(clinicaltrials.gov)
- P2 | N=600 | Not yet recruiting | Sponsor: AIM Vaccine Co., Ltd.
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 12, 2023
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: AIM Vaccine Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 13, 2023
Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older
(clinicaltrials.gov)
- P3 | N=9800 | Recruiting | Sponsor: AIM Vaccine Co., Ltd.
New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 19, 2022
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
(clinicaltrials.gov)
- P=N/A | N=350 | Recruiting | Sponsor: AIM Vaccine Co., Ltd. | Active, not recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL13 • IL2 • IL4
December 19, 2022
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
(clinicaltrials.gov)
- P=N/A | N=54 | Recruiting | Sponsor: AIM Vaccine Co., Ltd. | Active, not recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 28, 2022
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
(clinicaltrials.gov)
- P=N/A | N=54 | Active, not recruiting | Sponsor: AIM Vaccine Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 28, 2022
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
(clinicaltrials.gov)
- P=N/A | N=350 | Active, not recruiting | Sponsor: AIM Vaccine Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL13 • IL2 • IL4
1 to 10
Of
10
Go to page
1